Pretreatment albumin–bilirubin score and serum albumin in relation to a claims-defined fluid retention outcome during clazosentan treatment in older patients with subarachnoid hemorrhage: a multicenter retrospective cohort study
Year: 2026
Type: article
Abstract: Background Fluid retention is a frequent adverse event associated with clazosentan treatment in patients with subarachnoid hemorrhage (SAH). A previous single-center study suggested an association between the pretreatment albumin–bilirubin (ALBI) score and clazosentan-associated fluid retention, but the generalizability of this finding and the incremental predictive value of the ALBI score beyond serum albumin remain uncertain. This study examined the association between the pretreatment ALBI score and a claims-defined composite outcome related to fluid retention using a nationwide Diagnosis Procedure Combination database and compared the predictive performance of the ALBI score and serum albumin. Methods We conducted a retrospective cohort study using the Medical Data Vision database. Patients aged ≥ 65 years with available pretreatment serum albumin and total bilirubin measurements who received clazosentan were included. The primary outcome was a claims-defined composite of fluid retention-related diagnostic codes or intravenous loop diuretic administration during clazosentan treatment. Sequentially adjusted multivariable logistic regression models evaluated the associations of the pretreatment ALBI score and serum albumin with the composite outcome. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC) and corrected Akaike information criterion (AICc). Results Of 474 patients, 280 (59.1%) met the composite outcome definition, including 237 (84.6%) identified by intravenous loop diuretic administration alone. The ALBI score showed small, nearly unchanged effect estimates across five sequentially adjusted models (adjusted odds ratio [OR], 1.03–1.04 per 0.1-point increase), although statistical significance varied with covariate adjustment. Serum albumin showed similarly small estimates (adjusted OR, 1.02–1.03 per 0.1-g/dL decrease). In the fully adjusted models, neither the ALBI score (adjusted OR, 1.03; 95% confidence interval [CI], 0.989–1.08; p = 0.144) nor serum albumin (adjusted OR, 1.02; 95% CI, 0.986–1.06; p = 0.212) was significantly associated with the composite outcome. Conclusion Neither the pretreatment ALBI score nor serum albumin was significantly associated with the claims-defined composite outcome in fully adjusted models among older patients with SAH receiving clazosentan. Both markers showed limited incremental predictive value, and their clinical utility for individual risk prediction remains unestablished.
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7237340988
FWCI:
Cites:
Cited by:
Related to:
